Sun Pharma, Zydus sign licensing agreement for co-marketing of anaemia-associated CKD drug Desidustat
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Sun Pharmaceutical Industries and Zydus Lifesciences (including its subsidiaries/affiliates hereafter referred to as Zydus) announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is a first-of-its-kind oral treatment for anaemia associated with Chronic Kidney Disease (CKD) in India.
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket the product in India. Sun Pharma will market the drug under the brand name RYTSTAT. Zydus launched the drug under the brand name Oxemia in 2022 and will continue to market it. Zydus will receive upfront licensing income and is eligible to receive milestone income based on the achievement of pre-defined milestones.
Kirti Ganorkar, CEO – India Business, Sun Pharma said, “The addition of RYTSTAT further strengthens our nephrology portfolio in India. This partnership will allow greater access to critical therapy, helping millions of patients suffering from Chronic Kidney Disease. At Sun, it has always been our endeavour to introduce innovative products that help improve the quality of life of patients.”
A spokesperson from Zydus Lifesciences said, “Our life-changing discoveries are guided by the need to help patients and empower them with therapies that enable them to live healthier and more fulfilled lives. Desidustat, which is one of the critical treatment options for CKD patients, has substantially improved the patient’s quality of life since it is more convenient to take an oral pill instead of an injection that needs to be administered. We are pleased to join hands with Sun Pharma to expand the reach of this novel medicine by enabling access to more patients.”
